Division of HIV/AIDS Prevention,Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
Bureau of Epidemiology and Population Health,Michigan Department of Health and Human Services,Lansing, Michigan,USA.
Bureau of Epidemiology and Disease Control,Arizona Department of Health Services,Phoenix, Arizona,USA.
HIV Surveillance, TB, HIV, STD, and Viral Hepatitis, Connecticut Department of Public Health,Hartford, Connecticut,USA.
Bureau of Communicable Diseases,Florida Department of Health,Tallahassee, Florida,USA.
Bureau of Epidemiology,Houston Health Department,Houston, Texas,USA.
Bureau of HIV, STD, and Hepatitis, Iowa Department of Public Health,Des Moines, Iowa,USA.
Bureau of Infectious Diseases,Office of Public Health,Louisiana Department of Health,New Orleans, Louisiana,USA.
Prevention and Health Promotion Administration,Maryland Department of Health,Baltimore, Maryland,USA.
Bureau of Infectious Disease and Laboratory Sciences,Massachusetts Department of Public Health,Jamaica Plain, Massachusetts,USA.
Infectious Disease Epidemiology, Prevention, and Control,Minnesota Department of Health,Saint Paul, Minnesota,USA.
Bureau of HIV/AIDS Prevention and Control,New York City Department of Health and Mental Hygiene,New York, New York,USA.
Division of Disease Control,North Dakota Department of Health,Bismarck, North Dakota,USA.
Population Health Division,San Francisco Department of Public Health,San Francisco, California,USA.
Texas Department of State Health Services,Austin, Texas,USA.
Division of Disease Prevention,Virginia Department of Health,Richmond, Virginia,USA.
Infectious Disease Assessment Unit,Washington State Department of Health,Tumwater, Washington,USA.
Division of Public Health,Wisconsin Department of Health Services,Madison, Wisconsin,USA.
ICF International, Inc.,Atlanta, Georgia,USA.
Division of Viral Hepatitis,Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
Coinfection with human immunodeficiency virus (HIV) and viral hepatitis is associated with high morbidity and mortality in the absence of clinical management, making identification of these cases crucial. We examined characteristics of HIV and viral hepatitis coinfections by using surveillance data from 15 US states and two cities. Each jurisdiction used an automated deterministic matching method to link surveillance data for persons with reported acute and chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, to persons reported with HIV infection. Of the 504 398 persons living with diagnosed HIV infection at the end of 2014, 2.0% were coinfected with HBV and 6.7% were coinfected with HCV. Of the 269 884 persons ever reported with HBV, 5.2% were reported with HIV. Of the 1 093 050 persons ever reported with HCV, 4.3% were reported with HIV. A greater proportion of persons coinfected with HIV and HBV were males and blacks/African Americans, compared with those with HIV monoinfection. Persons who inject drugs represented a greater proportion of those coinfected with HIV and HCV, compared with those with HIV monoinfection. Matching HIV and viral hepatitis surveillance data highlights epidemiological characteristics of persons coinfected and can be used to routinely monitor health status and guide state and national public health interventions.